Stanford Cancer Institute
Showing 201-300 of 513 Results
-
Rogelio A. Hernández-López
Assistant Professor of Bioengineering and of Genetics
Current Research and Scholarly InterestsOur group works at the interface of mechanistic, synthetic, and systems biology to understand and program cellular recognition, communication, and organization. We are currently interested in engineering biomedical relevant cellular behaviors for cancer immunotherapy.
-
Daniel Herschlag
Professor of Biochemistry and, by courtesy, of Chemical Engineering
Current Research and Scholarly InterestsOur research is aimed at understanding the chemical and physical behavior underlying biological macromolecules and systems, as these behaviors define the capabilities and limitations of biology. Toward this end we study folding and catalysis by RNA, as well as catalysis by protein enzymes.
-
Mark Hlatky, MD
Professor of Health Policy, of Medicine (Cardiovascular Medicine), Emeritus
Current Research and Scholarly InterestsMy main research work is in "outcomes research", especially examining the field of cardiovascular medicine. Particular areas of interest are the integration of economic and quality of life data into randomized clinical trials, evidence-based medicine, decision models, and cost-effectiveness analysis. I am also interested in the application of novel genetic, biomarker, and imaging tests to assess risk and guide clinical management of coronary artery disease.
-
Andrew R. Hoffman
Professor of Medicine (Endocrinology), Emeritus
Current Research and Scholarly InterestsMechanism of genomic imprinting of insulin like growth factor-2 and other genes.Long range chromatin interactions Role of histone modifications and DNA methylation in gene expression.
-
Lawrence "Rusty" Hofmann, MD
Professor of Radiology (Interventional Radiology)
BioDr. Lawrence “Rusty” Hofmann is an actively practicing physician and Professor of Interventional Radiology at Stanford School of Medicine, as well as the Chief of Industry Partnerships for Stanford Healthcare, Medical Director of Cardiac and Interventional Services, and the Medical Director of Digital Health at Stanford Medicine. He served as Chief of Interventional Radiology at Stanford for nearly two decades. He is the Co-Founder of Grand Rounds, Inc, rebranded as Included Health. He has devoted his career to providing state-of-the-art care to patients at either Johns Hopkins, where he practiced for 10 years, or Stanford, where he practiced for 15 years. He has published over 100 scientific articles on minimally invasive treatment of blood clots (DVT) and cancer. He has always had in interest in innovation. He holds 2 patents, has worked as a consultant for numerous medical device companies, both start-ups and large companies and is currently the Global-Principal Investigator for the first clinical trial testing a venous stent. He has invented and brought a number of devices from napkin stage to world-wide use. He has active digital health research projects at the intersection of artificial intelligence and clinical care, including telemedicine and deep venous thrombosis.
-
Chris Holsinger, MD, FACS
Professor of Otolaryngology - Head & Neck Surgery (OHNS)
Master of Liberal Arts Student, admitted Autumn 2024Current Research and Scholarly InterestsDr. Holsinger’s surgical practice focuses on the surgical management of benign and malignant diseases of the thyroid, parathyroid and head and neck.
His areas of clinical interest include endoscopic head and neck surgery, including robotic thyroidectomy, transoral robotic surgery and transoral laser microsurgery, as well as time-honoured approaches of conservation laryngeal surgery, supracricoid partial laryngectomy. -
Jody Elizabeth Hooper
Professor of Pathology
Current Research and Scholarly InterestsI am the Director of the Research Autopsy Collaboration at Stanford (RACS) to collect organs and tissues from decedent donors for cancer and disease research. https://med.stanford.edu/racs
I have a number of research interests associated with my autopsy work, including how the time interval between death and collection (the PMI) affects the condition and research viability of the collected tissue, how valuable blood and tissue cultures behave after death, and how autopsy results affect clinical practice in an established information loop. I have projects exploring physician and family attitudes towards autopsy and the utilization of rapid autopsy tissue in characterizing cancer evolution from genetic and immunologic standpoints. -
Richard Hoppe
Henry S. Kaplan-Harry Lebeson Professor of Cancer Biology, Emeritus
Current Research and Scholarly InterestsIrradiation immunosuppression; total body irradiation;, psychosocial effects of cancer treatment; treatment of lymphoma;, mycosis fungoides.
-
Brooke Howitt
Irene Adler Professor
BioDr. Howitt is a gynecologic and sarcoma pathologist, with academic interests in gynecologic mesenchymal tumors and morphologic and clinical correlates of molecular alterations in gynecologic neoplasia.
-
Dimitre Hristov
Associate Professor of Radiation Oncology (Radiation Physics), Emeritus
Current Research and Scholarly InterestsDevelopment and integration of X-ray, MRI and US imaging technologies for radiation therapy guidance; Design of synergistic approaches to radiation therapy delivery; Treatment planning optimization and modeling.
-
Joe Le Hsu
Assistant Professor of Medicine (Pulmonary and Critical Care)
Current Research and Scholarly InterestsI am interested in understanding the host-pathogen interaction between Aspergillus fumigatus and the lung transplant recipient.
-
Robert Huang
Assistant Professor of Medicine (Gastroenterology and Hepatology)
Current Research and Scholarly InterestsEpidemiology
Epidemiology of gastric cancer
Racial and ethnic disparities in gastric cancer
Gastric intestinal metaplasia and other precancerous lesions
Molecular marker development
Microbiome -
Andrei Iagaru
Professor of Radiology (Nuclear Medicine)
Current Research and Scholarly InterestsCurrent research projects include:
1) PET/MRI and PET/CT for Early Cancer Detection
2) Targeted Radionuclide Therapy
3) Clinical Translation of Novel PET Radiopharmaceuticals; -
Debra M. Ikeda, M.D.
Professor of Radiology (Breast Imaging), Emerita
Current Research and Scholarly InterestsMy research interests are mammography positioning, tomosynthesis (DBT) cancer detection and diagnosis, MRI, DWI, MRI-guided breast biopsy, breast cancer recurrence, tattoo/ fiducial/wire localization of axillary lymph nodes, breast cancer and FDG PET-CT imaging, artifical intelligence/deep learning, breast density, density notification legislation, abscess drainages, mammography positioning
-
John P.A. Ioannidis
Professor of Medicine (Stanford Prevention Research Center), of Epidemiology and Population Health and, by courtesy, of Biomedical Data Science
Current Research and Scholarly InterestsMeta-research
Evidence-based medicine
Clinical and molecular epidemiology
Human genome epidemiology
Research design
Reporting of research
Empirical evaluation of bias in research
Randomized trials
Statistical methods and modeling
Meta-analysis and large-scale evidence
Prognosis, predictive, personalized, precision medicine and health
Sociology of science -
Michael Iv
Clinical Professor, Radiology
Current Research and Scholarly InterestsMy clinical and research interests include brain tumor and vascular imaging in both the adult and pediatric populations, incorporating advanced MR imaging techniques and analyses using qualitative and quantitative methods.
-
Peter K. Jackson
Professor of Microbiology and Immunology (Baxter Labs) and of Pathology
Current Research and Scholarly InterestsCell cycle and cyclin control of DNA replication .
-
Charlotte D. Jacobs M.D.
Drs. Ben and A. Jess Shenson Professor in the School of Medicine, Emerita
Current Research and Scholarly InterestsClinical Interests: general oncology, sarcomas. Research Interests: clinical trials in solid tumors.
-
Siddhartha Jaiswal
Associate Professor of Pathology
Current Research and Scholarly InterestsWe identified a common disorder of aging called clonal hematopoiesis of indeterminate potential (CHIP). CHIP occurs due to certain somatic mutations in blood stem cells and represents a precursor state for blood cancer, but is also associated with increased risk of cardiovascular disease and death. We hope to understand more about the biology and clinical implications of CHIP using human and model system studies.
-
Michelle L. James
Associate Professor of Radiology (Molecular Imaging Program at Stanford) and of Neurology and Neurological Sciences (Neurology Research)
Current Research and Scholarly InterestsThe primary aim of my lab is to improve the diagnosis and treatment of brain diseases by developing translational molecular imaging agents for visualizing neuroimmune interactions underlying conditions such as Alzheimer’s disease, multiple sclerosis, and stroke.
-
Ted Jardetzky
Professor of Structural Biology
On Partial Leave from 12/01/2025 To 02/28/2027Current Research and Scholarly InterestsThe Jardetzky laboratory is studying the structures and mechanisms of macromolecular complexes important in viral pathogenesis, allergic hypersensitivities and the regulation of cellular growth and differentiation, with an interest in uncovering novel conceptual approaches to intervening in disease processes. Ongoing research projects include studies of paramyxovirus and herpesvirus entry mechanisms, IgE-receptor structure and function and TGF-beta ligand signaling pathways.
-
Daniel Jarosz
Senior Associate Dean, Basic Science, Professor of Chemical and Systems Biology and of Developmental Biology
Current Research and Scholarly InterestsMy laboratory studies conformational switches in evolution, disease, and development. We focus on how molecular chaperones, proteins that help other biomolecules to fold, affect the phenotypic output of genetic variation. To do so we combine classical biochemistry and genetics with systems-level approaches. Ultimately we seek to understand how homeostatic mechanisms influence the acquisition of biological novelty and identify means of manipulating them for therapeutic and biosynthetic benefit.
-
Michael Jeng
Professor of Pediatrics (Hematology/Oncology)
Current Research and Scholarly InterestsResearch interests focus on: 1) histiocytic disorders, such as Langerhans cell histiocytosis (LCH) and hemophagocytic lymphohistiocytosis (HLH), and 2) vascular anomalies and malformations.
-
Kristin Jensen
Professor of Pathology
Current Research and Scholarly InterestsI am a clinical translational investigator with a primary interest in breast cancer biology, and the use of investigational and clinical ancillary techniques such as gene and tissue microarray analysis and immunohistochemistry in the diagnosis and prognosis of this disease. As a practicing cytopathologist, I also have an interest in improving the fine needle aspiration biopsy diagnosis of breast lesions, again using immunohistochemistry and gene expression analysis as adjuncts to cytomorphology.
-
Livnat Jerby
Assistant Professor of Genetics
Current Research and Scholarly InterestsCombining and advancing functional genomics, cell engineering, synthetic biology, AI, and basic immunology to uncover, decode, rewire, and develop mechanisms to selectively eliminate and reprogram disease-driving cells as a foundation for disease treatment and prevention.
-
Hanlee P. Ji
Professor of Medicine (Oncology) and, by courtesy of Electrical Engineering
Current Research and Scholarly InterestsCancer genomics and genetics, translational applications of next generation sequencing technologies, development of molecular signatures as prognostic and predictive biomarkers in oncology, primary genomic and proteomic technology development, cancer rearrangements, genome sequencing, big data analysis
-
Esther M. John
Professor (Research) of Epidemiology and Population Health and of Medicine (Oncology)
Current Research and Scholarly InterestsDr. John has extensive expertise in conducting population-based epidemiologic studies and has led as Principal Investigator multiple large-scale studies, including multi-center studies with a study site in the San Francisco Bay Area with its diverse population. Many of her studies and collaborations investigated cancer health disparities. Her research has focused on the role of modifiable lifestyle factors (e.g., body size, physical activity, diet), hormonal factors, early-life exposures, genetic variants, and gene-environment interactions; differences in risk factors by race and ethnicity, breast cancer subtypes, and prostate cancer subtypes; risk factors for familial breast cancer and second primary breast cancer, as well as prognostic factors related to survival disparities.
As Principal Investigator, Dr. John has led a number of studies conducted in the San Francisco Bay Area, including:
- the Northern California site of the Breast Cancer Family Registry, an on-going prospective multi-generational cohort of over 13,000 families established in 1995 at six international sites;
- the San Francisco Bay Area Breast Cancer Study, a population-based case-control study in nearly 5,000 African American, Hispanic, and non-Hispanic White women that investigated the role of modifiable lifestyle factors and other risk factors;
- the California site of the Breast Cancer Health Disparities Study that investigated genetic variability and breast cancer risk and survival in Hispanic and non-Hispanic White populations in the context of genetic admixture;
- the Breast Cancer Etiology in Minorities (BEM) Study, a pooled analysis of risk factors for breast cancer subtypes in minoritized racial and ethnic populations;
- the Northern California site of the WECARE Study that investigates risk factors for second primary contralateral breast cancer;
- the Second Primary Breast Cancer Disparities Study, a pooled analysis of risk factors for contralateral and ipsilateral second primary breast cancer in a diverse population;
- the San Francisco Bay Area Prostate Cancer Study, a population-based case-control study of lifestyle and genetic risk factors for advanced and localized disease.
These studies collected and pooled extensive data and biospecimens and continue to support numerous ancillary studies, collaborations and international consortia and have contributed to a better understanding of cancer risk and survival in minoritized racial and ethnic populations.
Dr. John is a founding PI of the LEGACY Girls Study, a prospective cohort established in 2011 that investigates early life exposures in relation to pubertal development outcomes, breast tissue characteristics, and behavioral and psychosocial outcomes in the context of having a family history or breast cancer.
In 2023, Dr. John joined the Stanford investigator team of the MOSAAIC (The Multiethnic Observational Study in American Asian and Pacific Islander Communities) Study, a five-center study to improve health of American Asian, Native Hawaiian, and Pacific Islander populations. -
Laura Johnston
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy), Emerita
Current Research and Scholarly InterestsClinical research in allogeneic and autologous hematopoietic cell transplantation (HCT), more specifically, allogeneic transplantation and graft versus host disease. Exploring methods of improving prevention and treatment of GVHD as well as the long term follow-up and/or quality of life of affected patients.
-
Anusha Kalbasi, MD
Associate Professor of Radiation Oncology (Radiation Therapy)
BioDr. Kalbasi is a physician-scientist at the Stanford Cancer Institute. In the clinic, Dr. Kalbasi is a radiation oncologist specializing in the treatment of patients with sarcoma and other solid tumors, with expertise in early phase clinical trials related to immunotherapy, cellular therapy, and radiation therapy.
The Kalbasi laboratory studies cancer immunology, with a focus on understanding—and re-engineering—the molecular conversations that immune cells have with one another and with cancer cells, especially through cytokines. By mapping how these signals are sent, received, and interpreted within immune cells and cancer cells, the lab aims to design next-generation immunotherapies that deliver the right messages at the right time—making cancer-fighting cells more potent, more persistent, and more precise. -
Aya Kamaya, MD
Professor of Radiology (Body Imaging)
On Partial Leave from 03/02/2026 To 04/17/2026Current Research and Scholarly InterestsHepatobiliary imaging
Hepatocellular carcinoma
Urologic imaging
Gynecologic imaging
Thyroid imaging
Novel ultrasound technologies
Perfusion CT imaging of abdominal tumors -
Michael J. Kaplan, MD
Professor of Otolaryngology - Head & Neck Surgery at the Stanford University Medical Center, Emeritus
Current Research and Scholarly Interests1) New therapeutic approaches for head and neck cancer, including immune stimulation possibilities (IRX-2 protocol), integration of biological modifiers, and, eventually, genetic approaches.
2) Head and neck cancer stem cells: identification, characterization, control--in conjunction with the Irv Weissman and Michael Clarke labs in the Stem Cell Institute
3) Development of innovative surgical methods at the anterior cranial base -
Daniel Kapp
Professor of Radiation Oncology, Emeritus
Current Research and Scholarly InterestsGynecologic malignancies; Rectal/and cancer; Breast Cancer; Hodgkin's disease; Hyperthermia; intraoperative radiation therapy; High dose rate radiation therapy; Predictive assays; Patterns of tumor spread; Health care finance.
-
Amer Karam
Clinical Professor, Obstetrics & Gynecology - Gynecologic Oncology
BioDr. Amer Karam is a board-certified, fellowship-trained gynecologic surgeon and clinical professor in the Stanford Medicine Department of Obstetrics & Gynecology, Division of Gynecology Oncology. He specializes in gynecologic oncology, hospice and palliative care, hereditary gynecologic cancers, laparoscopic and robotic gynecologic surgery, and obstetrics and gynecology.
Dr. Karam attended medical school at the American University in Beirut. He completed his internship and residency at the Johns Hopkins Hospital in Baltimore, Maryland, before completing a fellowship in gynecologic oncology at the University of California Los Angeles and a fellowship in breast surgery at the Memorial Sloan-Kettering Cancer Center. Dr. Karam has a vested interest in minimally invasive and robotic surgery with a practice centered on this approach for the treatment of patients with gynecologic malignancy and complicated pelvic surgery. He is currently director of Robotic Surgery and Outreach in the Division of Gynecologic Oncology. -
Maya M. Kasowski
Assistant Professor of Pathology, of Medicine (Pulmonary, Allergy and Critical Care Medicine) and, by courtesy, of Genetics
BioI am a clinical pathologist and assistant professor in the Departments of Medicine, Pathology, and Genetics (by courtesy) at Stanford. I completed my MD-PhD training at Yale University and my residency training and a post-doctoral fellowship in the Department of Genetics at Stanford University. My experiences as a clinical pathologist and genome scientist have made me passionate about applying cutting-edge technologies to primary patient specimens in order to characterize disease pathologies at the molecular level. The core focus of my lab is to study the mechanisms by which genetic variants influence the risk of disease through effects on intermediate molecular phenotypes.
-
Laurence Katznelson, MD
Professor of Neurosurgery, Emeritus
Current Research and Scholarly InterestsDr. Katznelson is an internationally known neuroendocrinologist and clinical researcher, with research expertise in the diagnosis and management of hypopituitarism, the effects of hormones on neurocognitive function, and the development of therapeutics for acromegaly and Cushings syndrome, and neuroendocrine tumors. Dr. Katznelson is the medical director of the multidisciplinary Stanford Pituitary Center, a program geared for patient management, clinical research and patient education
-
Mark A. Kay, M.D., Ph.D.
Dennis Farrey Family Professor of Pediatrics, and Professor of Genetics
Current Research and Scholarly InterestsMark A. Kay, M.D., Ph.D. Director of the Program in Human Gene Therapy and Professor in the Departments of Pediatrics and Genetics. Respected worldwide for his work in gene therapy for hemophilia, Dr. Kay and his laboratory focus on establishing the scientific principles and developing the technologies needed for achieving persistent and therapeutic levels of gene expression in vivo. The major disease models are hemophilia, hepatitis C, and hepatitis B viral infections.
-
Electron Kebebew, MD, FACS
Harry A. Oberhelman, Jr. and Mark L. Welton Professor
Current Research and Scholarly InterestsDr. Kebebew’s translational and clinical investigations have three main scientific goals: 1) to develop effective therapies for fatal, rare and neglected endocrine cancers, 2) to identify new methods, strategies and technologies for improving the diagnosis and treatment of endocrine neoplasms and the prognostication of endocrine cancers, and 3) to develop methods for precision treatment of endocrine tumors.
-
Ali Raza Khaki, MD
Clinical Assistant Professor, Medicine - Oncology
BioDr. Khaki is a medical oncologist and clinical assistant professor at Stanford University School of Medicine.
In his clinical practice, he treats patients with all forms of genitourinary cancer, including kidney, bladder, prostate, and testicular. He also regularly attends on the inpatient oncology service at Stanford Hospital.
With each patient, he is devoted to providing exceptional, humanistic care and has been recognized throughout his career for his humanism. As a medical student, he was named to the national Gold Humanism Honor Society and he received the Reza Gandjei Humanism Award as a medical resident at UCSF.
His research interests include novel therapies for genitourinary cancers, with a focus on urothelial cancer outcomes. He is the site principal investigator for multiple clinical trails investigating new therapies for genitourinary cancers.
Dr. Khaki is also active working clinically in inpatient oncology and is a Unit Based Medical Director for G1, an oncology hospital unit and is the Director of Inpatient Oncology. In this role, he oversees the inpatient oncology teams, works closely with the cancer center to develop new transitions of care pathways from inpatient to outpatient and has co-led an inpatient oncology research group to study quality improvement, care delivery and end-of-life care for patients with cancer.
Dr. Khaki has earned honors and recognition from the American Association for Cancer Research, American Society of Clinical Oncology, Bladder Cancer Advocacy Network, Conquer Cancer Foundation, and other organizations.
He has authored numerous articles on topics such as immunotherapy for urothelial cancer, management of cancer patients with COVID-19, and utilization of end-of-life care by cancer patients. In addition, he is an editor for HemOnc.org and theMednet, a physician-only online community where members share clinical questions and answers. -
Saad A. Khan, MD
Associate Professor of Medicine (Oncology)
BioDr. Khan is a fellowship-trained cancer specialist with board certification in oncology and hematology. He is an assistant professor in the Department of Medicine, Division of Oncology.
Dr. Khan focuses on the treatment of head and neck cancers, advanced thyroid cancers, and neuroendocrine tumors. He recognizes the broad effects of these conditions on daily living and aims to develop personalized, comprehensive treatment plans that optimize health and quality of life.
Dr. Khan’s research interests include therapeutic clinical trials as well as ways to reduce toxicities that some patients may experience when receiving cancer treatment. His research activities include ongoing clinical trials of targeted and immune therapy for aggressive thyroid cancer.
He has published numerous articles on his research discoveries in peer-reviewed journals such as the JAMA Oncology, Investigational New Drugs, and others. Topics include new drug treatments for small cell lung cancer and for cancers of the head and neck, racial and gender disparities in certain types of cancer, and management of the potentially toxic effects of cancer therapies.
Dr. Khan is a member of the NRG Head and Neck Committee. NRG brings together internationally recognized groups (the first words in their names form the acronym “NRG”) to conduct cancer clinical research and share study results. The objective is to inform clinical decision making and healthcare policy worldwide.
Dr. Khan is a member of the ECOG Head and Neck Core and Thoracic Committees. ECOG (Eastern Cooperative Oncology Group) is part of one of the five groups of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN) Program.
He also is a member of the National Cancer Institute’s Central IRB for Early Phase Clinical Trials.
When not providing patient care or conducting research, Dr. Khan enjoys spending time with his family, hiking, and relaxing at the beach. -
Paul A. Khavari, MD, PhD
Carl J. Herzog Professor of Dermatology in the School of Medicine
Current Research and Scholarly InterestsWe work in epithelial tissue as a model system to study stem cell biology, cancer and new molecular therapeutics. Epithelia cover external and internal body surfaces and undergo constant self-renewal while responding to diverse environmental stimuli. Epithelial homeostasis precisely balances stem cell-sustained proliferation and differentiation-associated cell death, a balance which is lost in many human diseases, including cancer, 90% of which arise in epithelial tissues.
-
Chaitan Khosla
Wells H. Rauser and Harold M. Petiprin Professor and Professor of Chemistry and, by courtesy, of Biochemistry
Current Research and Scholarly InterestsResearch in this laboratory focuses on problems where deep insights into enzymology and metabolism can be harnessed to improve human health.
For the past two decades, we have studied and engineered enzymatic assembly lines called polyketide synthases that catalyze the biosynthesis of structurally complex and medicinally fascinating antibiotics in bacteria. An example of such an assembly line is found in the erythromycin biosynthetic pathway. Our current focus is on understanding the structure and mechanism of this polyketide synthase. At the same time, we are developing methods to decode the vast and growing number of orphan polyketide assembly lines in the sequence databases.
For more than a decade, we have also investigated the pathogenesis of celiac disease, an autoimmune disorder of the small intestine, with the goal of discovering therapies and related management tools for this widespread but overlooked disease. Ongoing efforts focus on understanding the pivotal role of transglutaminase 2 in triggering the inflammatory response to dietary gluten in the celiac intestine. -
Butrus Khuri-Yakub
Professor (Research) of Electrical Engineering, Emeritus
BioButrus (Pierre) T. Khuri-Yakub is a Professor of Electrical Engineering at Stanford University. He received the BS degree from the American University of Beirut, the MS degree from Dartmouth College, and the Ph.D. degree from Stanford University, all in electrical engineering. His current research interests include medical ultrasound imaging and therapy, ultrasound neuro-stimulation, chemical/biological sensors, gas flow and energy flow sensing, micromachined ultrasonic transducers, and ultrasonic fluid ejectors. He has authored over 600 publications and has been principal inventor or co-inventor of 107 US and international issued patents. He was awarded the Medal of the City of Bordeaux in 1983 for his contributions to Nondestructive Evaluation, the Distinguished Advisor Award of the School of Engineering at Stanford University in 1987, the Distinguished Lecturer Award of the IEEE UFFC society in 1999, a Stanford University Outstanding Inventor Award in 2004, Distinguished Alumnus Award of the School of Engineering of the American University of Beirut in 2005, Stanford Biodesign Certificate of Appreciation for commitment to educate, mentor and inspire Biodesgin Fellows, 2011, and 2011 recipient of IEEE Rayleigh award.
-
Seung K. Kim M.D., Ph.D.
KM Mulberry Professor, Professor of Developmental Biology, of Medicine (Endocrinology) and, by courtesy, of Pediatrics (Endocrinology)
Current Research and Scholarly InterestsWe study the development of pancreatic islet cells using molecular, embryologic and genetic methods in several model systems, including mice, pigs, human pancreas, embryonic stem cells, and Drosophila. Our work suggests that critical factors required for islet development are also needed to maintain essential functions of the mature islet. These approaches have informed efforts to generate replacement islets from renewable sources for diabetes.
-
Yong Yean Kim
Assistant Professor of Pediatrics ( Hematology & Oncology)
BioOur lab is interested in translational science to bring new therapies to clinical trials. In particular, we are interested in pediatric sarcomas which have not had advancement in clinical treatment for decades. Current projects in the lab focus on understanding of the biology of fusion transcription factor PAX3::FOXO1 which is the driver mutation in fusion positive rhabdomyosarcoma. PAX3::FOXO1 is a powerful oncogenic transcription factor which rewires the transcriptional organization to lock the cancer cell in the proliferative state. Since transcription factors including PAX3::FOXO1 are difficult to target using small molecules, we aim to understand how PAX3::FOXO1 is regulated and targeting the regulators of PAX3::FOXO1. By understanding and targeting the regulation of PAX3::FOXO1, we hope to bring new therapies for fusion positive rhabdomyosarcoma. Additionally, these regulatory mechanisms may also be active in other transcription driven cancers such as the EWSR1::FLI1 driven Ewings Sarcoma.
Our lab is also interested in exploring the epigenetic landscape of pediatric solid tumors and trying to understand how dysregulation in the epigenome drives oncogenesis. We utilize various CRISPR mediated genetic techniques to interrogate the regulators of epigenome focusing on the histone lysine demethylases (KDMs). KDMs are an understudied group of epigenetic regulators which can be targeted for therapeutic effect. We explore the role of KDMs in pediatric solid tumors and hope to identify potential targets for drug development. -
Youn H Kim, MD
The Joanne and Peter Haas, Jr., Professor for Cutaneous Lymphoma Research and Professor, by courtesy, of Medicine (Oncology)
Current Research and Scholarly InterestsClinical research in cutaneous lymphomas, especially, mycosis fungoides; studies of prognostic factors, long-term survival results, and effects of therapies. Collaborative research with Departments of Pathology and Oncology in basic mechanisms of cutaneous lymphomas. Clinical trials of new investigative therapies for various dermatologic conditions or clinical trials of known therapies for new indications.
-
Abby C. King
David and Susan Heckerman Professor and Professor of Epidemiology & Population Health and of Medicine (Stanford Prevention Research Center)
Current Research and Scholarly InterestsMy interests include applications of behavioral theory and social ecological approaches to achieve large scale changes impacting chronic disease prevention and control; expanding the reach and translation of evidence-based interventions through state-of-the-art technologies; exploring social and physical environmental influences on health; applying community participatory research perspectives to address health disparities; and policy-level approaches to health promotion/disease prevention.
-
Amanda Kirane, MD, PhD, FACS, FSSO
Associate Professor of Surgery (General Surgery)
BioDr. Kirane is a fellowship-trained, board-certified specialist in complex general surgical oncology. She is an Assistant Professor in the Department of Surgery, Section of Surgical Oncology, at Stanford University School of Medicine. Dr. Kirane serves as Director of Cutaneous Surgical Oncology at the Stanford Cancer Center and her clinical practice focuses on the diagnosis and treatment of melanoma and other skin cancers. She partners closely with patients and families to provide the most effective treatment approach possible. For each patient, she tailors an evidence-based, personalized care plan that is innovative, comprehensive, and compassionate.
Dr. Kirane is Principal Investigator of multiple studies in melanoma and mechanisms of resistance to immunotherapy, with focus on myeloid biology. Her current interests include immune response and novel therapies in melanoma, predictive modeling of patient responses using organoid technology, and translational biomarker development. She has led research into immune therapy for earlier stage melanoma using regionally directed therapy to augment immune response in melanoma and trials in surgical care in melanoma.
The National Institutes of Health, American Society of Clinical Oncology, the Melanoma Research Alliance, and others have funded her research. She has co-authored articles on her discoveries in the Journal of Clinical Investigation, Nature Communications, Nature Genetics, Cancer Research, Journal of Surgical Oncology, Annals of Surgery, Annals of Surgical Oncology, and elsewhere. Topics include intratumoral therapy, biomarker development, macrophage biology in melanoma and immunotheraputic resistance, and patient-derived organoid modeling. Dr. Kirane has presented updates on the management of melanoma and other cancers to her peers at meetings of the American College of Surgeons, Society of Surgical Oncology, and Society for Immunotherapy in Cancer.
Dr. Kirane has earned awards for her achievements in clinical care, research, and scholarship. The Society for Immunotherapy of Cancer, Society of Surgical Oncology, Memorial Sloan Kettering Cancer Center, and other prestigious organizations have honored her work. She is a fellow of the American College of Surgeons (FACS) and Society of Surgical Oncology (FSSO). She is a member of the Society for Immunotherapy of Cancer, American Association of Cancer Research, Society for Melanoma Research, Connective Tissue Oncology Society, Association of Academic Surgeons, and Association of Women Surgeons.
She volunteers her time and expertise on behalf of the Melanoma Research Foundation, members of her community in need, STEM programs for girls, and other initiatives. She also is fellowship trained in Physician Wellness and Wellbeing and teaches somatic technique, mindfulness-based stress reduction, meditation, and breathwork. -
Susan Knox
Associate Professor of Radiation Oncology, Emerita
Current Research and Scholarly InterestsOur interests include 1) study of the effect of radiation on regulatory cell subpopulations and co-stimulatory molecules, 2) use of radiation as an immune modulator for optimization of transplant regimens, 3) the role of radiation in tumor vaccine strategies, 4) study of new radiosensitizers and radioprotectors, and 5) discovery of new targeted therapies for the treatment of solid tumors.
-
Matthew Kohrman
Associate Professor of Anthropology, and by courtesy, of Medicine (Stanford Prevention and Research Center) and Senior Fellow, by courtesy, at the Freeman Spogli Institute for International Studies
BioMatthew Kohrman’s research and writing bring anthropological methods to bear on the ways health, culture, and politics are interrelated. Focusing on the People's Republic of China, he engages various intellectual terrains such as governmentality, gender theory, political economy, critical science studies, narrativity, and embodiment. His first monograph, Bodies of Difference: Experiences of Disability and Institutional Advocacy in the Making of Modern China, raises questions about how embodied aspects of human existence, such as our gender, such as our ability to propel ourselves through space as walkers, cyclists and workers, become founts for the building of new state apparatuses of social provision, in particular, disability-advocacy organizations. Over the last decade, Prof. Kohrman has been involved in research aimed at analyzing and intervening in the biopolitics of cigarette smoking among Chinese citizens. This work, as seen in his recently edited volume--Poisonous Pandas: Chinese Cigarette Manufacturing in Critical Historical Perspectives--expands upon heuristic themes of his earlier disability research and engages in novel ways techniques of public health, political philosophy, and spatial history. More recently, he has begun projects linking ongoing interests at the intersection of phenomenology and political economy with questions regarding environmental attunement and the arts.
-
Christina Kong
Professor of Pathology
Current Research and Scholarly InterestsImproving the accuracy of cytologic diagnosis through the use of ancillary techniques on specimens obtained by fine needle aspiration biopsy.
Identifying potential indicators of prognosis in head and neck squamous cell carcinomas.
Evaluating the utility of immunohistochemical stains in refining the diagnosis of squamous dysplasia of the cervix, vulva, and head and neck. -
Eric Kool
George A. and Hilda M. Daubert Professor of Chemistry
Current Research and Scholarly Interests• Design of cell-permeable reagents for profiling, modifying, and controlling RNAs
• Developing fluorescent probes of DNA repair pathways, with applications in cancer, aging, and neurodegenerative disease
• Discovery and development of small-molecule modulators of DNA repair enzymes, with focus on cancer and inflammation -
Nishita Kothary, MD
Professor of Radiology (Interventional Radiology)
Current Research and Scholarly InterestsInterventional Oncology: Percutaneous and transarterial interventions for diagnosis and treatment of primary and metastatic tumors (lung, liver and renal)
Research Interest:
Gastrointestinal and Hepatic Oncology -
Mark Krasnow
Paul and Mildred Berg Professor
Current Research and Scholarly Interests- Lung development and stem cells
- Neural circuits of breathing and speaking
- Lung diseases including lung cancer
- New genetic model organism for biology, behavior, health and conservation -
Anandi Krishnan
Affiliate, Institute for Immunity, Transplantation, and Infection Operations
Visiting Scholar, Institute for Immunity, Transplantation, and Infection OperationsBioDr. Krishnan is a translational scientist with experiences in engineering, biosciences, molecular genetics and hematology. Having recently completed her NIH clinical scientist career development award (NHGRI 1K08HG010061-01A1, 2018-24), and NIH-supported research re-entry (NCATS 3UL1TR001085-04S1, 2016-18), Anandi’s interests are in expanding our understanding of the multifaceted function of anucleate blood platelets and their parent megakaryocytes in human disease.
Her current work, applying platelet transcriptome profiling and machine learning principles, aims to nominate novel clinically relevant strategies for personalized cancer and antiplatelet/antithrombotic therapy. Continued development of this research is likely to identify key mechanistic variables in platelet- and megakaryocyte-specific response to health and disease.
Recent contributions in both computational and mechanistic components of platelet and blood research lay the groundwork for sustaining contributions to the field of hematology genomic medicine (e.g. Shen et al PMID 34755136, Seetharam et al PMID 36712071, Kelliher et al PMID 37961700, Thomas & Krishnan PMID 38175681, Abbonante et al PMID 38165147, Jutzi et al PMID 35763665, Campbell et al PMID 36194487). Anandi was also was one of the first non-MD PhD scientist to be awarded the NHGRI K08 Clinical Scientist Research Career Development Award, the HTRS Mid-Career Research Award, and the MPN Research Foundation Challenge Grant Award, reflecting her consistent efforts bridging basic and clinical disciplines.
Select other recognitions include:
Member, Editorial Board, Journal of Thrombosis and Haemostasis (2024-)
Ad hoc Reviewer, NIH CSR Cancer and Hematological Disorders Study Section (2023, 24)
Host Mentor, ISTH Training Fellowship, International Society for Thrombosis and Haemostasis (2023)
Member, Minority Recruitment Initiatives Subcommittee, American Society of Hematology (2022-26)
Team Science Leadership Program at Stanford Medicine (2022)
Peer Mentor, Pathology Stanford Network for Advancement and Promotion (2021)
Research Mentor, Meharry Medical College, Nashville, Meharry-Stanford initiative *mentee selected for oral presentation & won 2nd place at Meharry (2021)
Thrombosis & Hemostasis Societies of North America Young Investigator Award (2020)
Invited Member and Panelist, NSF RESET Conference (2020)
Invited Member/Panelist, iRelaunch Return to Work Conference, Stanford Alumni Association (2018)
Featured twice by NIH NCATS in the ‘Features & Briefs’ & ‘Diversity Awardee Profiles’ webpages (2017,18)
Complete list of publications: https://pubmed.ncbi.nlm.nih.gov/?term=anandi+krishnan&sort_order=asc -
Calvin Kuo
Maureen Lyles D'Ambrogio Professor
Current Research and Scholarly InterestsWe study cancer biology, intestinal stem cells (ISC), and angiogenesis. We use primary organoid cultures of diverse tissues and tumor biopsies for immunotherapy modeling, oncogene functional screening and stem cell biology. Angiogenesis projects include blood-brain barrier regulation, stroke therapeutics and anti-angiogenic cancer therapy. ISC projects apply organoid culture and ko mice to injury-inducible vs homeostatic stem cells and symmetric division mechanisms.
-
Allison W. Kurian, M.D., M.Sc.
Professor of Medicine (Oncology) and of Epidemiology and Population Health
Current Research and Scholarly InterestsI aim to understand cancer burden and improve treatment quality at the population level. I have a strong focus on genetic risk assessment and precision oncology. I lead epidemiologic studies of cancer risk factors, clinical trials of novel approaches to cancer risk reduction, and decision analyses of strategies to optimize cancer outcomes.
-
David Kurtz
Adjunct Clinical Assistant Professor, Medicine - Oncology
Current Research and Scholarly InterestsImplementation of noninvasive detection of malignancies in the clinic remains difficult due to both technical and clinical challenges. These include necessary improvements in sensitivity and specificity of biomarkers, as well as demonstration of clinical utility of these assays. My research focuses on technical development and implementation of assays to detect and track cancers in order to facilitate personalized disease management.
-
Bernice Kwong, MD
Clinical Professor, Dermatology
BioBernice Kwong, M.D., is Clinical Professor of Dermatology, Director of the Supportive Dermato-Oncology Program, and Director of the Inpatient Dermatology Consult Service. She has a special interest in the management of cutaneous complications that arise in hospitalized patients and cancer patients. She runs the Supportive Dermato-Oncology Program at the Stanford Cancer Center, where she manages skin side effects of cancer therapies including chemotherapy-related skin reactions, radiation dermatitis, and graft-versus-host disease. Dr. Kwong completed medical school at Yale University, and completed her dermatology residency at Stanford University in 2012.
-
Norman J. Lacayo, MD
Associate Professor of Pediatrics (Hematology and Oncology)
Current Research and Scholarly InterestsPediatric Hematology/Oncology, Phase I drug studies for refractory and relapsed leukemia; genomic studies, biologic risk-stratification and treatment of acute myeloid leukemia; prediction or induction response and risk of relapse using phosphoproteomics in childhood AML; novel MRD techniques in childhood ALL.
-
Uri Ladabaum
Professor of Medicine (Gastroenterology and Hepatology)
Current Research and Scholarly InterestsGastrointestinal cancer prevention and risk management. Risk stratification. Cost-effectiveness analysis. Health services research.
-
Sheila Lahijani, MD, FACLP
Clinical Professor, Psychiatry and Behavioral Sciences - Medical Psychiatry
Clinical Professor (By courtesy), Medicine - OncologyBioDr. Lahijani is a Clinical Professor at Stanford University School of Medicine and a nationally recognized leader in psycho-oncology. With extensive training and expertise in internal medicine, psychiatry, and consultation-liaison psychiatry, she has made significant contributions to the integration of psychiatric care within oncological settings.
Since her appointment at Stanford in 2015, Dr. Lahijani has served as the lead psychiatric oncologist at the Stanford Cancer Center, where she provides medical psychiatric consultation services and collaborates with interdisciplinary teams to enhance patient outcomes. In her capacity as Medical Director of the Stanford Cancer Center Psychosocial Oncology Program, a position she has held since 2019, she is responsible for the strategic development and implementation of comprehensive psychiatric services tailored to the unique needs of patients with cancer.
Additionally, Dr. Lahijani serves as the Section Chief of Psycho-Oncology in the Division of Medical Psychiatry where she oversees psych-onc faculty development and leads the training of medical psychiatry fellows in psycho-oncology. She also supervises advanced practice providers while also working as an attending psychiatric oncologist to provide care for patients with complex medical and psychiatric comorbidities across all hematology and oncology units.
Dr. Lahijani's academic credentials include her graduation from Brown Medical School, followed by the completion of a combined residency in Internal Medicine and Psychiatry at Rush University Medical Center. After completing residency, she practiced internal medicine and psychiatry with a focus on triple diagnosis (HIV, addiction medicine, mental health). She then further advanced through a Psychosomatic Medicine Fellowship at Northwestern University's Feinberg School of Medicine, during which time she received specialized training in psychiatric oncology at the Lurie Comprehensive Cancer Center and Memorial Sloan Kettering Cancer Center.
Her clinical expertise encompasses psychopharmacology and a range of treatment modalities, including Meaning Centered Psychotherapy and Dignity Therapy. Dr. Lahijani is deeply committed to fostering relationship-centered skills and promoting provider wellness. As a faculty member of Advancing Communication Excellence at Stanford, she has led workshops designed to enhance communication competencies among faculty and staff.
Dr. Lahijani's scholarly pursuits are at the intersection of medicine and psychiatry, with a particular emphasis on the neuropsychiatric sequelae of cancer treatment, innovations in care, and medical education. She is dedicated to the education and mentorship of trainees in Psychiatry, Internal Medicine, Hematology/Oncology, and Neurology. Through her commitment to academic excellence, Dr. Lahijani plays a pivotal role in preparing the next generation of healthcare providers to adeptly navigate the intricate and multifaceted needs of patients and their caregivers, thereby promoting a comprehensive approach to patient care. -
Marvin Langston
Assistant Professor of Epidemiology and Population Health and, by courtesy, of Urology
BioDr. Marvin Langston is an Assistant Professor of Epidemiology and Population Health. He is a member of the Stanford Cancer Institute and Urologic Cancer Epidemiology Lab. He is an epidemiologist by training who focuses on the fields of benign prostate and pelvic conditions and urological cancers including prostate and kidney cancers.
Prior to Stanford, he served as a Research Scientist in the Division of Research at Kaiser Permanente Northern California. Dr. Langston received his PhD in Epidemiology from the University of Arizona’s College of Public Health followed by postdoctoral training in Cancer Prevention and Control at Washington University in Saint Louis School of Medicine.
His program of research intends to characterize and measure infectious agents, environmental toxicants, and lifestyle factors; to evaluate the role of these factors in urological cancer etiology and outcomes; and to identify populations at high risk of exposure to these factors. So far he has focused this research to address the following questions: 1) What role do sexually transmitted infections and other systemic infections have in prostate damage and ensuing prostate cancer risk? 2) How can we appropriately model and define early life risk factors for urological cancers? 3) Can we harmonize molecular and clinical aspects of urological condition diagnoses to produce well characterized outcomes for biomarker discovery and etiological investigation? He has primarily addressed these questions using a variety of molecular and clinical epidemiology approaches while developing expertise in the cross-cutting theme of cancer health disparities with particular interests in the cancer care experiences of sexual and gender minorities and racial/ethnic minorities.
Dr. Langston has been studying the impact of exogenous factors on prostate specific antigen (PSA) concentration in young men as a marker of prostate damage and inflammation for over a decade. As early life PSA has been found predictive of future prostate cancer mortality, he has now setout to optimize risk-stratified screening for prostate cancer. This promising approach uses men’s baseline PSA values to inform their risk of future aggressive and/or fatal prostate cancer and determine their frequency of further screening. Under this approach, men with high baseline age-specific total PSA levels receive more frequent screening and men with lower levels receive less frequent screening. Dr. Langston was awarded an R01 from NCI to evaluate this approach using historically collected biospecimen. His funded research trajectory to this point also includes four training awards (2-NCI and 2-NIDDK) and several internal grants. Dr. Langston was selected in the inaugural class of the White House Cancer Moonshot Scholars for his work. -
Philip W. Lavori
Professor of Biomedical Data Science, Emeritus
Current Research and Scholarly InterestsBiostatistics, clinical trials, longitudinal studies, casual inference from observational studies, genetic tissue banking, informed consent. Trial designs for dynamic (adaptive) treatment regimes, psychiatric research, cancer.
-
Quynh-Thu Le, MD, FACR, FASTRO, FARS
Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Professor, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS)
Current Research and Scholarly InterestsMy laboratory focuses on identifying pathways and biomarkers of treatment resistance in head and neck cancer using clinical samples. We explore approaches to modulate these pathways through preclinical models (cell lines, organoids, tumor bearing mice) in order to develop precise strategies against these resistant mechanisms. At the same time, we are also studying pathways involved in treatment-related toxicity and develop strategies to prevent or overcome these toxicities.
-
Byrne Lee, MD FACS
Clinical Professor, Surgery - General Surgery
BioDr. Lee is a native of New York City. He attended the Sophie Davis School of Biomedical Education at the City College of New York and received his medical degree from New York Medical College. He completed general surgery residency training at Lenox Hill Hospital and fellowship training in surgical oncology at the City of Hope National Cancer Center. Dr. Lee led the Peritoneal Surface Malignancy Program at City of Hope prior to joining Stanford in 2019.
Dr. Lee is a surgical oncologist who specializes in the treatment of gastrointestinal malignancies. He has dedicated his clinical practice to the surgical management of metastatic disease, particularly to the liver and peritoneum. He has expertise in delivering regional cancer therapies such as heated intraperitoneal chemotherapy (HIPEC). Additionally, he performs surgery for cancers of the stomach, liver, pancreas, small intestine, colon, and soft tissue sarcoma. He utilizes minimally invasive and robotic surgical techniques when appropriate.
Dr. Lee leads the Regional Cancer Therapies program at Stanford. The program implements and develops novel treatment strategies for patients affected with peritoneal malignancies and oligometastatic disease to the liver. His research focus is on clinical outcomes of multidisciplinary management for gastric, hepatobiliary, and peritoneal surface malignancies. He is a member of a national consensus group performing collaborative research and developing clinical trials for HIPEC surgeries. -
Jennifer Lee
Professor of Medicine (Endocrinology) and, by courtesy, of Epidemiology and Population Health
Current Research and Scholarly InterestsI am a healthcare lead and physician scientist for innovation, R&D, and advanced analytics, and oversee these aspects at VA Palo Alto/VHA, within Stanford-VA relationship. The VA has the US's largest health care system and longest running EHR. I prioritize enabling multiple partners (industry, government, academia, foundations), to innovate/R&D in the VA health care system. We prioritize mentoring students from various Schools to become future leaders in R&D, innovation, and healthcare.
-
John Leppert
Professor of Urology and, by courtesy, of Nephrology
Current Research and Scholarly InterestsOur research aims to improve the global quality of care for patients with Urologic Cancer with a particular focus on kidney cancer. We are investigating novel proteomic platforms and assays to diagnose kidney cancer and predict response to therapy. We are evaluating the comparative effectiveness of various kidney cancer surgeries and their impact on chronic kidney disease and its downstream effects. We are applying epidemiology, bioinformatics, and health services methods to urologic conditions.
-
Craig Levin
Professor of Radiology (Molecular Imaging Program at Stanford/Nuclear Medicine) and, by courtesy, of Physics, of Electrical Engineering and of Bioengineering
Current Research and Scholarly InterestsMolecular Imaging Instrumentation
Laboratory
Our research interests involve the development of novel instrumentation and software algorithms for in vivo imaging of cellular and molecular signatures of disease in humans and small laboratory animal subjects. -
Ronald Levy, MD
Robert K. and Helen K. Summy Professor in the School of Medicine
Current Research and Scholarly InterestsClinical Interests: lymphoma. Research Interests: Immunology and molecular biology of lymphoid malignancy; molecular vaccines for cancer.
-
David B. Lewis
Naddisy Foundation Professor of Pediatric Food Allergy, Immunology, and Asthma
Current Research and Scholarly InterestsMy laboratory is focused on defining cellular and molecular mechanisms that limit T cell responses to vaccines and pathogens during normal early postnatal development and in cases of inherited genetic immunodeficiencies. We are also determinomg how these limitations in immunity can be overcome by using novel approaches for vaccine adjuvants for influenza vaccine and by using catalytically inactive Cas proteins for inducing endogenous gene expression.
-
Gordon Li, MD
Professor of Neurosurgery and, by courtesy, of Neurology and Neurological Sciences and of Otolaryngology - Head & Neck Surgery (OHNS)
Current Research and Scholarly Interests1.) My laboratory studies the biology of brain tumors with the goal of developing novel therapeutics for the treatment of malignant brain tumors and translating that research into clinical trials.
2.) My clinical interests include improving surgical techniques for brain tumor surgery, immunotherapy for the treatment of glioblastoma, and novel uses for stereotactic radiosurgery. -
Jin Billy Li
Professor of Genetics
Current Research and Scholarly InterestsThe Li Lab is primarily interested in RNA editing mediated by ADAR enzymes. We co-discovered that the major function of RNA editing is to label endogenous dsRNAs as "self" to avoid being recognized as "non-self" by MDA5, a host innate immune dsRNA sensor, leading us to pursue therapeutic applications in cancer, autoimmune diseases, and viral infection. The other major direction of the lab is to develop technologies to harness endogenous ADAR enzymes for site-specific transcriptome engineering.
-
Lingyin Li
Professor of Biochemistry
BioDr. Li is a professor in the Biochemistry Department and ChEM-H Institute at Stanford. She is also a core investigator of the Arc Institute. Her lab works on understanding biochemical mechanisms of the immunotransmitter cGAMP and harnessing it to treat cancer and autoimmunity. She majored in chemistry at University of Science and Technology of China and graduated with a B. En in 2003. She then trained with Dr. Laura Kiessling, a pioneer in chemical biology, at University of Wisconsin-Madison and graduated with a Ph.D in chemistry in 2010. She obtained her postdoctoral training with Dr. Timothy Mitchison at Harvard Medical School, who introduced her to the field of chemical immunology. She started her lab at Stanford in 2015.
-
Ruijiang Li
Associate Professor of Radiation Oncology (Radiation Physics)
Current Research and Scholarly InterestsMy lab's research is focused on the development of imaging and molecular biomarkers to improve cancer detection, diagnosis, prognostication, and prediction of therapy response. Our ultimate goal is to translate these biomarkers into clinical practice to guide optimal management and therapeutic decisions for precision cancer medicine.
-
Joseph C. Liao
Kathryn Simmons Stamey Professor
Current Research and Scholarly InterestsThe overarching theme of my scholarship is to develop precision diagnostics in imaging and biomarkers to guide the delivery of precision therapy for urological diseases including bladder cancer, urinary tract infections, and kidney stone disease.
-
Michael Lim, M.D.
Stanford Medicine Endowed Chair of the Department of Neurosurgery, Professor of Neurosurgery and, by courtesy, of Radiation Oncology, of Medicine, of Otolaryngology - Head & Neck Surgery (OHNS) and of Neurology and Neurological Sciences
BioDr. Lim is the Chair of the Department of Neurosurgery and a board-certified neurosurgeon specializing in brain tumors and trigeminal neuralgia.
Dr. Lim’s clinical interests include the treatment of benign and malignant brain tumors, with special interest in gliomas, meningiomas, metastatic tumors, and skull base tumors. Dr. Lim also specializes in surgical treatments for trigeminal neuralgia. During his time at Johns Hopkins, Dr. Lim built one of the largest brain tumor and trigeminal neuralgia practices and utilized the most advanced surgical technologies and techniques for his patients. As a passionate voice for patient experience, he has been recognized by his peers and patients for his integrity and compassionate care, including a Service Excellence Award from HealthNetwork Foundation.
As a mentor, he has garnered numerous teaching awards, including being honored as an outstanding teacher by Johns Hopkins University School of Medicine. He is actively involved in shaping education for neurosurgery and oncology across the United States and around the world. He is the recipient of the prestigious 2023 Abhijit Guha Award in Neuro-Oncology.
Dr. Lim’s research interests focus on harnessing the immune system to fight cancer. His laboratory focuses on understanding mechanisms of immune evasion by cancer cells. He has successfully translated his findings from the laboratory to the clinics and has conducted and led several large national immunotherapy clinical trials for brain tumors.
Dr. Lim’s bibliography contains well over 300 articles on topics such as immunotherapy for glioblastoma, long-term survival of glioma patients treated with stereotactic radiation, and treatment of neuropathic pain. His work has appeared in Science Translational Medicine, Clinical Cancer Research, Lancet Oncology, Nature Immunology, and many more publications. He also has written 20 book chapters and monographs.
Dr. Lim is a world leader in immunotherapy for brain tumors. In addition to being invited world-wide to give lectures and seminars, he has given platform presentations on the topics of immunotherapy for brain tumors, neurosurgical techniques and management of brain tumors at the American Society of Clinical Oncologists, American Academy of Neurological Surgeons, Radiological Society of North America, Annual Symposium on Brain and Spine Metastases, Congress of Neurological Surgeons, and other meetings. In addition, he has served as platform chairman of the CNS session at the American Society for Clinical Oncology conference.
Dr. Lim is a member of the American Society for Clinical Oncology, Congress of Neurological Surgeons, American Association of Neurological Surgeons, and Society for Neuro-Oncology. Dr. Lim served as the program co-chair of the Society for Neuro-Oncology and CNS section of the American Society for Clinical Oncology. He also served on many executive committees, including the Executive Committee for the Joint Tumor Section of the American Association of Neurological Surgeons and Congress of Neurological Surgeons.
Trigeminal neuralgia treatment: https://www.youtube.com/watch?v=-n8nvwkwZik
Trigeminal neuralgia patient stories: https://www.youtube.com/watch?v=kClePRPYlQs&t=1s -
Michael Lin
Professor of Neurobiology, of Bioengineering and, by courtesy, of Chemical and Systems Biology
Current Research and Scholarly InterestsOur lab applies biochemical and engineering principles to the development of protein-based tools for investigating biology in living animals. Topics of investigation include fluorescent protein-based voltage indicators, synthetic light-controllable proteins, bioluminescent reporters, and applications to studying animal models of disease.
-
Bruce Ling
Senior Research Scientist, Pediatrics - Neonatology
Current Research and Scholarly InterestsA significant focus of my career is the use of AI to decode real-world datasets of electronic health records, high-resolution LCMS-based liquid/tissue biopsy proteomics/metabolomics, and multiple modality medical imaging.
-
Michael Link
Lydia J. Lee Professor of Pediatric Cancer
Current Research and Scholarly InterestsHematology/Oncology, treatment of sarcomas of bone and soft tissue, biology of acute lymphoblastic leukemias, treatment of non-Hodgkin's lymphoma and Hodgkin's disease.
-
Eleni Linos, MD, MPH, DrPH
Ben Davenport and Lucy Zhang Professor of Medicine, Professor, of Medicine (Center for Digital Health) and, by courtesy, of Epidemiology and Population Health
BioEleni Linos MD, MPH, DrPH, is the Director of the Stanford Center for Digital Health. She is a Professor of Dermatology and Epidemiology at Stanford University. Dr. Linos also serves as an Associate Dean for Research at Stanford Medicine, leading the training and mentoring of the next generation of translational research scientists.
Dr. Linos' research focuses on the use of technology in health, dermatology, public health, cancer prevention and the care of older adults. She is dually trained in epidemiology and dermatology and is the principal investigator of several NIH funded studies aimed at improving the lives of patients worldwide. She received her undergraduate degree from Trinity College, Cambridge and medical degree from Christ Church College, Oxford University in the UK. She then received a master’s and doctoral degree from the Harvard School of Public Health and completed her residency in Dermatology at Stanford University.
Linos has been continuously funded by the NIH since 2016, as principal investigator of several studies on technology, aging and dermatology. Her scholarly output includes over 200 peer-reviewed publications, an h-index of 51, and more than 10,000 citations across disciplines. Linos was awarded the NIH Director’s New Innovator Award and received the Paul Beeson Emerging Leaders Award in Aging.
As the Director of the Stanford Center for Digital Health, she has built and led infrastructure bringing together scientists and industry leaders across all Stanford schools to catalyze research across the fields of medicine, computer science, engineering, robotics, policy and public health.
Dr. Linos is committed to mentorship and training of the next generation of scientists in translational research. She has personally mentored over 60 physician-scientists, many of whom are now independently-funded investigators and leaders in academic medicine. She also serves as the co-PI of Stanford CTSA’s K12 Program, responsible for mentorship and training of 10 translational science faculty each year. Over the last seven years, she is funded by an NIH K24 mentorship grant award to mentor the next generation of physician-scientists in dermatology. In addition, Linos is committed to mentorship and supporting students across all levels of education to pursue their passions including students in high school and undergraduates.
Clinically, Dr. Linos is a Board Certified Dermatologist and cares for patients with skin disease in the Stanford Dermatology teaching clinics. -
Douglas Liou
Clinical Associate Professor, Cardiothoracic Surgery
BioDr. Liou is a local product, having grown up in Salinas and graduated from U.C. Berkeley with a degree in Molecular and Cell Biology. He received his M.D. from New York Medical College and completed his General Surgery training at Cedars-Sinai Medical Center in Los Angeles. At Cedars, he was recognized for his excellence in clinical care and research with numerous awards and publications. Dr. Liou recently completed his 2 years of Thoracic Surgery training at Stanford, during which time he proved to be an outstanding physician and surgeon and a dedicated clinical researcher.
Dr. Liou’s expertise includes all surgical diseases of the lung, mediastinum, esophagus, chest wall, and diaphragm, with particular interest in thoracic oncology and minimally invasive surgical techniques. He has extensive experience with minimally invasive and open management of lung and esophageal cancer, mediastinal tumors, and benign esophageal disease. Dr. Liou's primary research focus has been on clinical outcomes in thoracic oncology and quality improvement.
Dr. Liou practices out of Stanford Hospital main campus and Stanford Health Care-ValleyCare Hospital in Pleasanton, where he is starting Stanford's Thoracic Surgery program in the East Bay. -
Joseph (Joe) Lipsick
Professor of Pathology and of Genetics
Current Research and Scholarly InterestsFunction and evolution of the Myb oncogene family; function and evolution of E2F transcriptional regulators and RB tumor suppressors; epigenetic regulation of chromatin and chromosomes; cancer genetics.
-
Jafi Alyssa Lipson
Clinical Associate Professor, Radiology
Current Research and Scholarly InterestsDr. Lipson's research interests include breast density and breast cancer risk assessment; informatics applications in breast imaging; early breast cancer detection and extent of disease evaluation using contrast enhanced mammography, digital breast tomosynthesis, and high resolution breast MRI; novel blood and imaging biomarkers of breast cancer burden and neoadjuvant treatment response; and image-guided wireless localization techniques for breast surgery.
-
Kyle Loh
Associate Professor of Developmental Biology (Stem Cell)
BioHow the richly varied cell-types in the human body arise from one embryonic cell is a marvel and mystery. We have mapped how human embryonic stem cells develop into over twenty different types of cells. This roadmap allowed us to generate enriched populations of human brain, blood, blood vessel, bone, and other cells in a Petri dish from embryonic stem cells, with implications for developmental biology, stem cell biology, and regenerative medicine. Additionally, we have an emerging interest in exploring deadly biosafety level 4 viruses together with our collaborators.
Kyle attended the County College of Morris and Rutgers, and received his Ph.D. from Stanford (working with Irving Weissman), with fellowships from the Hertz Foundation, National Science Foundation and Davidson Institute for Talent Development. He then continued as a Siebel Investigator, and later, as an faculty member at Stanford. Kyle is a Packard Fellow, Pew Scholar, Human Frontier Science Program Young Investigator and Baxter Foundation Faculty Scholar. His research has been recognized by the NIH Director's Early Independence Award, ISSCR Early Career Impact Award, Forbes 30 Under 30, Harold Weintraub Graduate Award, Hertz Foundation Thesis Prize and A*STAR Investigatorship. -
Teri A Longacre
Richard L. Kempson, MD, Professor in Surgical Pathology
Current Research and Scholarly InterestsGynecological, breast and gastrointestinal pathology with major emphasis on ovarian cancer and ovarian tumors of low malignant potential. Pathology of familial and hereditary breast-ovarian-GI cancer.
-
Dr. Michael T. Longaker
Deane P. and Louise Mitchell Professor in the School of Medicine and Professor, by courtesy, of Materials Science and Engineering
Current Research and Scholarly InterestsWe have six main areas of current interest: 1) Cranial Suture Developmental Biology, 2) Distraction Osteogenesis, 3) Fibroblast heterogeneity and fibrosis repair, 4) Scarless Fetal Wound Healing, 5) Skeletal Stem Cells, 6) Novel Gene and Stem Cell Therapeutic Approaches.
-
Billy W Loo Jr, MD PhD FASTRO FACR
Professor of Radiation Oncology (Radiation Therapy)
Current Research and Scholarly InterestsMy clinical specialty is precision targeted radiotherapy of thoracic cancers.
My research is on developing next-generation ultra-rapid radiotherapy technology (PHASER) and studying the radiobiological effects of FLASH treatment.
My clinical research is on advanced 4-D image-guided radiotherapy and stereotactic ablative radiotherapy (SABR), and functional and metabolic imaging and imaging biomarkers. -
Karl Lorenz
Professor of Medicine (Primary Care and Population Health)
BioDr. Karl Lorenz, MD MSHS is a general internal medicine and palliative care physician, and Section chief of the VA Palo Alto-Stanford Palliative Care Program. Formerly at the VA Greater Los Angeles, Dr. Lorenz directed palliative care research at the VA Center for Innovation to Implementation and served on the faculty at the UCLA School of Medicine. Dr. Lorenz is a member of the VA’s national Hospice and Palliative Care Program (HPC) leadership team, director of the operational palliative care Quality Improvement Resource Center (QuIRC), and adjunct facility staff member at RAND. Dr. Lorenz’s work and leadership has been influential to the field of palliative care research. Under Dr. Lorenz’s leadership, since 2009 the Quality Improvement Resource Center (QuIRC) has served as one of three national leadership Centers responsible for strategic and operational support of the VA’s national hospice and palliative care programs. QuIRC develops and implements provider facing electronic tools for the VA’s national electronic medical record to improve the quality of palliative care. In that role, Dr. Lorenz participates with the national leadership team in strategic planning, policy development, and providing resources to support operational efforts. Dr. Lorenz has contributed to the field of global palliative care, serving the World Health Organization in its development of Palliative Care for Older People and leading methods for Palliative Care Essential Medications.
-
Kate Lorig
Professor (Research) of Medicine (Immunology and Rheumatology), Emerita
Current Research and Scholarly InterestsCommunity based psycoeducational intervention studies of disease self management for people with chronic diseases. arthritis, lung diseases, heart disease AIDs, low back pain and diabetes. Programs and studies in Spanish and English. Interventions are in small groups, mailed or on the Internet.
-
Alarice Cheng-Yi Lowe
Associate Professor of Pathology
BioDr. Lowe joined the School of Medicine faculty in 2019. She received her undergraduate degree in Biology from MIT and her medical degree at UCSD, prior to residency and cytology fellowship at UCLA. In 2011, she joined the faculty at Brigham and Women's Hospital where she developed a research focus on Circulating Tumor Cells (CTCs) and the application of new technology to improve clinical and molecular diagnostics. Clinically, her interests focus on Cytopathology and Genitourinary Pathology.
-
Anson Lowe
Associate Professor of Medicine (Gastroenterology and Hepatology), Emeritus
Current Research and Scholarly InterestsThe laboratory is focused on the relationship between injury, wound healing, and cancer. Esophageal, gastric, and pancreatic cancers are a focus. We are particularly interested in the regulation of cell signaling by EGFR, the EGF receptor. In addition to cancer pathogenesis, active projects include the development of new diagnostic assays and drugs.
-
Robert Lowsky
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Current Research and Scholarly InterestsDr. Lowsky's research is focused on understanding the role of regulatory T cells in the prevention of GVHD and in promoting immune tolerance following organ transplantation.
